Lundbeck's Exciting Presentations at the AAN Annual Meeting
H. Lundbeck A/S (Lundbeck) is set to unveil positive interim results from its ongoing efforts at the upcoming American Academy of Neurology (AAN) Annual Meeting. This includes vital insights into the PACIFIC trial focused on bexicaserin, showcasing Lundbeck's commitment to addressing the complex challenges associated with developmental and epileptic encephalopathies (DEEs).
PACIFIC Trial Findings
The PACIFIC trial is a landmark investigation into bexicaserin, a promising new treatment aimed at combatting seizures in DEEs, which represent one of the most challenging and severe forms of epilepsy. These conditions often lead to drug-resistant seizures, significantly affecting a patient's quality of life. The forthcoming AAN session will highlight six-month results from the open-label extension of the Phase 1b/2a trial, reinforcing the potential of bexicaserin in treating these challenging conditions.
Addressing Unmet Medical Needs
With over 900 genes linked to DEEs, the complexity of these conditions leaves many patients without effective treatment options. Lundbeck's ongoing research demonstrates a growing commitment to fill this gap. According to Johan Luthman, EVP and Head of Research & Development at Lundbeck, the positive data emerging from the PACIFIC trial suggests that bexicaserin may provide meaningful benefits to many individuals affected by DEEs.
Trial Highlights and Results
The open-label extension of the PACIFIC trial has shown a generally favorable safety and tolerability profile for bexicaserin after six months of treatment. Notably, all treatment-naive patients transitioned successfully from a placebo to bexicaserin, confirming its tolerability. The interim analysis reported a striking 57.3% reduction in countable motor seizures and a 61.2% reduction in total seizures during this period. More than half of the newly treated patients noted at least a 50% reduction from baseline, underscoring the potential efficacy of this novel treatment.
Insights on Eptinezumab
In addition to the findings on bexicaserin, Lundbeck will also present compelling analyses and real-world data regarding eptinezumab. This research focuses on clinically meaningful endpoints, including the frequency of good days experienced by patients and sustained treatment response over time.
Transformative Impact on Migraine Treatment
For many, debilitating migraines significantly limit daily activities, and the holistic understanding of their impact on quality of life is crucial. Lundbeck aims to elevate expectations in preventive migraine treatment, ensuring patients receive effective options tailored to their individual needs.
Details of Lundbeck's AAN Presentations
Key presentations at the AAN 2025 will include:
- Bexicaserin Oral Presentation: Exploring safety, tolerability, and efficacy in participants with DEEs on April 7 during Session S20.
- Eptinezumab Poster Presentations: Covering long-term maintenance of migraine responses and the patient-reported impacts of migraine treatments.
About Bexicaserin
Bexicaserin (LP352) is an innovative oral treatment that acts as a superagonist on the 5-HT2C receptors and is currently undergoing a global Phase III program. It has been granted Breakthrough Therapy Designation for the treatment of seizures associated with DEEs in patients aged two and older. While promising, it remains an investigational compound that is not yet approved for marketing.
About Eptinezumab
Eptinezumab is a humanized monoclonal antibody developed specifically for intravenous use and targets calcitonin gene-related peptide (CGRP) to prevent migraines. It has shown significant efficacy in reducing the number of migraine days in clinical trials and is currently available in multiple markets globally.
About H. Lundbeck A/S
Lundbeck stands as a dedicated biopharmaceutical leader in brain health, actively working to improve the quality of life for those suffering from neurological and psychiatric disorders. With a workforce of approximately 5,500 and a presence in more than 80 countries, their mission is underscored by a commitment to innovative solutions that address critical health challenges in neurology. Lundbeck is focused on advancing treatments that can genuinely transform the lives of patients.
Frequently Asked Questions
What is the PACIFIC trial?
The PACIFIC trial investigates the efficacy and safety of bexicaserin in treating seizures associated with Developmental and Epileptic Encephalopathies.
When will Lundbeck present its findings?
Lundbeck's findings will be presented during the American Academy of Neurology Annual Meeting.
What is eptinezumab?
Eptinezumab is a monoclonal antibody treatment aimed at preventing migraines by blocking specific proteins associated with migraine attacks.
What are the key results from the trial?
The initial results from the OLE showed significant reductions in both countable motor seizures and total seizures for patients treated with bexicaserin.
How is Lundbeck contributing to neurological health?
Lundbeck focuses on research and development in neuroscience, dedicated to producing innovative treatments for complex neurological conditions.
